Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France

被引:0
作者
Xavier Colin
Antoine Lafuma
Dominique Costagliola
Erik Smets
Josephine Mauskopf
Pascal Guillon
机构
[1] 43 Boulevard du Maréchal Joffre,Cemka
[2] INSERM,Eval
[3] Unité Mixte de Recherche (UMR) S 720,RTI HEALTH Solutions
[4] and Université Pierre et Marie Curie-Paris 6,undefined
[5] UMR S 720,undefined
[6] Johnson & Johnson Pharmaceutical Services LLC,undefined
[7] Research Triangle Park,undefined
[8] Janssen Cilag SAS,undefined
来源
PharmacoEconomics | 2010年 / 28卷
关键词
Budget Impact; Darunavir; Enfuvirtide; Tipranavir; Optimize Background Regimen;
D O I
暂无
中图分类号
学科分类号
摘要
Background: A key element for payers in the assessment of the economic profile of a medication is its anticipated impact on the evolution of healthcare budgets.
引用
收藏
页码:183 / 197
页数:14
相关论文
共 97 条
[1]  
Palella FJ(1998)Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 853-60
[2]  
Delaney KM(2006)The survival benefits of AIDS treatment in the United States J Infect Dis 194 11-9
[3]  
Moorman AC(2003)Twenty years of therapy for HIV-1 infection Nat Med 9 867-73
[4]  
Walensky RP(2006)The lifetime cost of current human immunodeficiency virus care in the United States Med Care 44 990-7
[5]  
Paltiel D(1997)Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres AIDS 11 101-5
[6]  
Losina E(2003)Decline in the AIDS and death rates in the EuroSIDA Study: an observational study Lancet 362 22-9
[7]  
Pomerantz RJ(2003)Rates and risk factors for condition-specific hospitalizations in HIV infected and uninfected women J Acquir Immune Defic Syndr 34 320-30
[8]  
Horn DL(2003)Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection Health Policy 65 261-7
[9]  
Schackman BR(2007)Approach to the treatment-experienced patient Infect Dis Clin North Am 21 85-102
[10]  
Gebo KA(2006)British HIV Association (BHIVA) draft guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) HIV Med 7 487-503